Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPULSE: Lefitolimod Maintenance in SCLC
NCT02200081Phase 2Completed
- Sponsor
- Mologen AG
- Start
- Mar 2014
- Primary completion
- Nov 2016
- Modality
- Antisense DNA, Prophylactic Vaccines, Small Interfering RNA (siRNA)
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial in small cell lung cancer (SCLC) comparing MGN1703 with Standard of Care (2 arms). Primary endpoint: Overall Survival at 24 months. Started Mar 2014; status: completed.
02
Drugs
lefitolimod
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02200081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02200081.